Candel Therapeutics Inc (CADL)vsRevolution Medicines Inc (RVMD)
CADL
Candel Therapeutics Inc
$8.51
-8.20%
HEALTHCARE · Cap: $627.19M
RVMD
Revolution Medicines Inc
$169.77
+0.15%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates 2294% more annual revenue ($742,000 vs $31,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
CADL
Avoid24
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CADL
The strongest argument for CADL centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CADL
The primary concerns for CADL are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
CADL is growing revenue faster at 0.0% — sustainability is the question.
CADL generates stronger free cash flow (-19M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CADL scores higher overall (24/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Candel Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Candel Therapeutics Inc. is an innovative biotechnology firm dedicated to advancing cancer treatment through its proprietary oncolytic virus technology, which selectively targets malignant cells while sparing healthy tissue. The company boasts a robust pipeline that encompasses multiple hard-to-treat cancers, enhancing anti-tumor immunity and aiming to provide significant therapeutic breakthroughs. With a strong intellectual property portfolio and collaborations with premier research institutions, Candel is strategically positioned to lead transformative developments in oncology, ultimately aiming to improve patient outcomes and redefine standard care in cancer therapy.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?